A carregar...
EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer
IMPORTANCE: Nivolumab and epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are now the standard-of-care therapies in non–small cell lung cancer (NSCLC). Although EGFR-TKIs are well understood and have well-defined safety profiles, our experience with immune checkpoint inhibito...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5885195/ https://ncbi.nlm.nih.gov/pubmed/29327061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.4526 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|